Since the introduction of imatinib just over a decade ago, there has been a dramatic change in the treatment and prognosis of early chronic phase chronic myeloid leukaemia (CML). This review article focuses on recent advances, culminating in the approval of nilotinib by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed CML in the chronic phase.
Introduction
Since approximately 90% of patients are diagnosed with chronic myeloid leukaemia (CML) in the early chronic phase (ECP), in this article we focus on this group and do not discuss the management of advanced phase disease. Since the introduction of imatinib just over a decade ago, there has been a dramatic change in the treatment and prognosis of Philadelphia chromosome positive ECP CML. Prior to the introduction of imatinib, the median survival of newly diagnosed CML patients was approximately 5 years and nontransplant treatment options were limited primarily to hydroxyurea or interferon [Silver et al. 1999 ]. In the last 10 years there has been a considerable improvement in response rates in ECP CML with a corresponding improvement in survival, such that the majority of patients with newly diagnosed CML can expect to enjoy normal life expectancy, provided that they remain compliant with long-term therapy. As such, our treatment expectations have grown significantly over the last 10 years. There is now an increasing emphasis on optimizing responses in all patients to ensure that they can enjoy as near normal life expectancy as possible with minimal impact on quality of life [Baccarani et al. 2009a] .
First, in this article we review the results obtained with imatinib 400 mg daily, including a recent update on the International randomized study of interferon versus STI571 (IRIS) trial, and important lessons learned from this study. Second, we discuss trials aimed at improving on this standard approach with the aim of early optimization of treatment. This will cover the role of high-dose imatinib as initial treatment, whether there is any role for a combination with interferon and the results of a number of phase II trials with nilotinib and dasatinib. Finally, the article will conclude with the preliminary results of phase III trials comparing nilotinib and dasatinib, respectively, with standard dose imatinib.
Update on the IRIS trial and the importance of early response An analysis of the annual rate of events after achievement of complete cytogenetic response (CCyR) on first-line imatinib from the IRIS trial demonstrates that even patients in CCyR remain at risk of progression to accelerated phase or blast crisis within the first 3 years of therapy. In contrast, no patient achieving a major molecular response (MMR) by 12 months subsequently progressed [Deininger et al. 2009 ]. As such, MMR is now recognized as an optimal goal of therapy in CML since patients who achieve this so called 'safe haven' have a very low probability of subsequent progression with continued therapy [Baccarani et al. 2009a ].
In general, patients who achieve a more rapid molecular response appear to have a higher likelihood of both achieving a subsequent MMR and a lower likelihood of progressing. In an analysis of the Australasian subset of the IRIS trial, Hughes and Branford showed that patients with a <1 log reduction at 3 months had only a 13% probability of MMR at 24 months compared with patients with a >12 log reduction and patients with a >2 log reduction at 3 months who had a subsequent probability of MMR at 24 months of 69% and 100%, respectively [Hughes and Branford, 2006] .
A similar exercise was performed at the MD Anderson Cancer Center (MDACC) evaluating the outcome of patients treated there with 400800 mg imatinib as primary therapy [Quintas-Cardama et al. 2009 ]. In patients with <1 log reduction at 3 months the probability of a subsequent MMR was 33% with a 13% risk of later progression. In contrast for patients with >2 log reduction at 3 months the probability of subsequent MMR was 84% and the risk of later progression only 3%. This suggests that early optimization of response may improve longterm outcome. Early optimization is the basis of a number of clinical trials in patients with newly diagnosed CML.
Clinical trials attempting to improve on the results with standard-dose imatinib (400 mg daily) as initial therapy of CML include the use of higher doses of imatinib (600800 mg daily), the addition of interferon and the use of the newer more potent second-generation tyrosine kinases (TKIs) such as nilotinib and dasatinib.
High-dose imatinib and combination with interferon as initial therapy
The first experience with high-dose imatinib (800 mg/day) in the front-line setting was in a single-centre phase II study from MDACC, showing a rapid, high rate of complete cytogenetic response in newly diagnosed patients with chronic-phase CML [Kantarjian et al. 2004] . This led to several randomized phase III studies comparing higher doses of imatinib (600800 mg) with standard dose imatinib (400 mg/day) in newly diagnosed CML patients. These include the French SPIRIT study, the German CML IV study and the international TOPS study [Baccarani et al. 2009b; Guilhot et al. 2009; Hehlmann et al. 2009 ].
The early results of the TOPS study were encouraging with more rapid onset of CCyR and MMR with imatinib 800 mg daily versus 400 mg daily at 3 and 6 months, but by 12 months, the differences in response rates were no longer statistically significant [Cortes et al. 2008 ]. On intent to treat analysis, the most recent update at the 2009 American Society of Hematology (ASH) meeting confirmed the lack of advantage for 800 mg daily over 400 mg daily for all major endpoints at 24 months of follow up with no significant difference in CCyR (76% versus 76%, respectively; p ¼ 1.00), MMR (51% versus 54%, respectively; p ¼ 0.626), event-free survival (EFS) (95% versus 95%, respectively; p ¼ 0.71), progression-free survival (PFS) (98% versus 97%, respectively; p ¼ 0.64), or overall survival (OS) (98% versus 97%, respectively; p ¼ 0.70) [Baccarani et al. 2009b] . Adverse events were more frequent among patients treated with high-dose imatinib with a higher proportion of patients on 800 mg discontinuing treatment (12% versus 5%). Among patients who were able to tolerate at least 600 mg daily, a significantly higher response rate was observed (p < 0.001), supporting a correlation of dose intensity with response in newly diagnosed patients treated and suggesting that the main limitation of high-dose imatinib is poor intolerance. While at present there is no difference between the two arms it is still possible that differences may emerge with longer follow up, including the possibility that the more rapid response rate achieved by 800 mg daily will translate into a higher proportion of patients achieving complete molecular response.
In addition to increasing the dose intensity of imatinib, an important research question since the initial introduction of imatinib has been whether there would be any benefit from combining imatinib with previous standards of care for CML, such as interferon or cytarabine. This was supported by early preclinical data that demonstrated in vitro synergy between these drugs and imatinib [Thiesing et al. 2000 ]. The French SPIRIT investigators recently reported at ASH the 2-year follow up of this multicentre phase III trial where 636 participants were randomized to receive treatment with one of four treatment arms: standard-or high-dose imatinib (600 mg) alone, or standard-dose imatinib with either pegylated interferon (90 mg/week) or low-dose cytarabine ]. At baseline, 40% and 27% of patients had low and high Sokal scores, respectively. The results of this trial showed a benefit in favour of the addition of pegylated interferon to standard-dose imatinib compared with the other treatment arms, with improvement in the rate of MMR (71% versus 4863%, respectively; p < 0.001), 4 log reduction (46% versus 2634%, respectively; p ¼ 0.006) and undetectable minimal residual disease (22% versus 1011%, respectively; p ¼ 0.0028). However, there was increased haematological toxicity in the interferon arm (grade 3 or 4 neutropenia and thrombocytopenia of 49% and 11%, respectively) and by 12 months on study 45% of patients in this arm had discontinued treatment with pegylated interferon. Importantly, the benefit of adding pegylated interferon was seen primarily in patients who could tolerate continued combination treatment beyond 1 year. Using a cut-off of 12.6 months the investigators noted that patients still on pegylated interferon beyond this time point had an 81% rate of achieving MMR compared with <50% rate in those who had already discontinued the drug. As yet, it is too early to know whether the benefit in terms of molecular response will translate into more meaningful outcomes, such as PFS or even the ability to stop therapy altogether. Considerably longer follow up is required to address these issues. Precisely how treatment with interferon could increase the depth of response in CML is unclear although possibilities could include immune modulation or targeting CML at the stem-cell level. With regards to the latter, it has recently been shown that following treatment with interferon, murine haematopoietic stem cells efficiently exit G(0) and enter an active cell cycle [Essers et al. 2009 ]. Potentially, therefore, interferon could prime the normally quiescent and resistant CML stem cell for successful eradication by TKI therapy. Clearly the challenge will be to find a dose and schedule of interferon that does not result in a high rate of discontinuation while preserving its efficacy.
In contrast to both the TOPS and the French SPIRIT studies, the German CML IV study found that higher-dose imatinib was associated with an increased likelihood of MMR at 12 months compared with standard-dose imatinib, with no apparent benefit to the addition of interferon [Hehlmann et al. 2009 ]. This large phase III trial randomized 1015 newly diagnosed CML patients between standard-dose imatinib (400 mg daily), high-dose imatinib (800 mg daily) or standard-dose imatinib plus interferon alpha 3 days/week. At 12 months 61% of patients treated with imatinib 800 mg daily achieved MMR compared with 45% treated with imatinib 400 mg daily (p ¼ 0.0009) and 42% of patients receiving imatinib 400 mg daily plus interferon (p ¼ 0.0001). No differences have yet been noted in terms of PFS or OS between the treatment arms with estimated 5-year PFS and OS rates for the whole study population at 89% and 92%, respectively. The improved response rate associated with high-dose imatinib was not without cost, with more frequent haematologic and gastrointestinal toxicity (42% versus 2930%), and oedema (33% versus 2026%).
Overall, the weight of evidence from these studies supports dose intensity, but clearly demonstrates that tolerance with high-dose imatinib is frequently poor. Could second-generation TKIs deliver the necessary dose intensity without compromising tolerability?
Second-generation TKIs as initial treatment (phase II) Both nilotinib and dasatinib are many times more potent than imatinib and have been associated with promising efficacy and safety in patients with imatinib failure [Giles, 2009] . As secondline therapy they induce rapid responses with a median time to major cytogenetic response (MCyR) of approximately 3 months suggesting that in ECP it should be possible to rapidly induce CCyR and MMR in the majority of patients [Hochhaus et al. 2008; Kantarjian et al. 2007] . Given that they are more potent BCR-ABL inhibitors, more intensive kinase inhibition from the onset of initial treatment could reduce genomic instability induced by BCR-ABL and reduce the risk of subsequent mutations [Burke and Carroll, 2010] . By rapidly achieving MMR and suppressing genomic instability, the risk of early progression should then be minimized. A final hypothesis is that more potent kinase inhibition would result in depletion of the CML stem cell pool to an even greater extent than imatinib allowing treatment discontinuation in a higher proportion of patients than may currently be the case with imatinib ].
At ASH 2009, Cortes and colleagues reported on the outcome of a phase II trial involving 67 patients with newly diagnosed CML treated with nilotinib 400 mg, with a median follow up of 21 months ]. Overall the risk profile of this group was favourable with 73% and 4% of patients having low and high Sokal risk scores, respectively. With this treatment cytogenetic responses occurred rapidly, with 95% of patients achieving a CCyR by 12 months. By comparison, in a previous study at MDACC, imatinib 400 mg daily had shown a complete cytogenetic response rate at 1 year of 65%. Molecular responses also occurred rapidly on nilotinib with 75% of patients achieving an MMR by 6 months, 5% of whom achieved CMR. By 12 months, 81% of patients achieved MMR (the primary endpoint of the study), 10% of whom achieved CMR.
At 36 months, the EFS rate (which included loss of complete haematologic response or MCyR, progression to AP/BC, death, or discontinuation due to toxicity) was 92% and 98% of patients remained free of progression to accelerated phase or blast crisis. OS at 36 months was 100%.
The treatment was well tolerated with infrequent grade 3 or 4 nonhaematologic toxicities, the most common of which were increased serum bilirubin (7%), increased serum lipase (4%), hyperglycaemia (4%), and pain (4%). The most common toxicities of any grade were fatigue, pain, rash, increased AST/ALT and hyperglycaemia, all of which were seen in approximately 4060% of patients. Consistent with what was seen in previous trials, nilotinib was associated with low rates of grade 3 or 4 myelosuppression. Grade 3 or 4 neutropenia, thrombocytopenia and anemia were seen in 11%, 13% and 6% of patients, respectively. This compares favourably with the experience of imatinib 400 mg daily in the IRIS trial, where the incidence of grade 3 or 4 neutropenia and thrombocytopenia was 17% and 9%, respectively.
At ASH 2009 Cortes and colleagues also reported on the outcome of an ongoing phase II randomized trial involving 72 patients with newly diagnosed CML treated with dasatinib (either 100 mg once daily or 50 mg twice daily), with a median follow up of 25 months ]. The twice-daily arm was subsequently closed. Baseline demographics in this study were very similar to the nilotinib phase II study with 72% and 7% of patients having low and high Sokal risk scores, respectively. Overall 96% of patients achieved CCyR in this study, with almost all achieving this landmark within 12 months (94% of total). MMR and CMR were seen in 79% and 11% of patients, respectively. The kinetics of molecular response were similar to that seen with nilotinib with 64%, 74% and 89% of patients achieving MMR by 6, 12 and 24 months, respectively. Two-year EFS (where events included loss of CHR, loss of MCyR, discontinuations for toxicity, progression to advanced disease or death) and OS were promising at 90% and 100%, respectively. Importantly, no patient progressed to accelerated phase or blast crisis. Thus, in terms of efficacy the responses achieved with dasatinib and nilotinib in patients with a similar Sokal risk profile appear very similar. With short-term follow up, the main difference between the two drugs is with respect to their toxicity profiles. In the dasatinib ECP phase II study, the 100 mg once-daily dosing schedule appeared to have a lower incidence of side effects compared with 50 mg twice daily. However, despite the use of the once-daily schedule, at least 10% of patients experienced grade 3 or 4 fatigue or musculoskeletal pain, with 5% of patients experiencing headache, diarrhoea, dyspnoea and neuropathy of grade 3 or 4 severity. The most common toxicities of any grade were fatigue, pain, headache, diarrhoea, dyspnoea, nausea, rash, oedema and dizziness, all of which were seen in approximately 4080% of patients. Pleural effusions of any grade were seen in 13% of patients treated with 100 mg once daily (21% with 50 mg twice daily), with 5% of patients at this dose developing pleural effusions of grade 3 or 4 pleural severity.
Compared with the phase II results from MDACC with nilotinib, dasatinib appeared to have greater potential for grade 3 or 4 myelosuppression. Grade 3 or 4 neutropenia, thrombocytopenia and anaemia were seen in 29%, 24% and 8% of patients, respectively.
Two other phase II studies, the GIMEMA and ICORG studies, have looked at the efficacy of nilotinib as treatment of early chronic phase CML [O'Dwyer et al. 2010; Rosti et al. 2009 ]. Similar to the MDACC study, the GIMEMA study treated patients with nilotinib 400 mg twice daily [Rosti et al. 2009 ]. This multicentre study included a lower proportion of low-risk Sokal patients than the MDACC study (45% versus 73%) with a significantly higher proportion of high-risk patients (14% versus 4%). The primary endpoint of this study was the rate of CCyR at 12 months with molecular response a secondary endpoint. Seventy three patients were enrolled and were followed up for a median of 15 months. By intention to treat analysis, the CCyR rate at both 6 and 12 months (the primary endpoint) was 96%. In terms of the molecular response the results bear a close similarity to those achieved at MDACC with 66% and 85% of patients achieving MMR at 6 and 12 months, respectively. While the numbers were small there was a suggestion that patients with high Sokal risk had a slightly lower and less rapid response than other patients with 5 of 10 high-risk patients (50%) in CCyR at 3 months compared with 83% of non-high-risk Sokal patients. At 12 months the respective figures for CCyR were 90% and 97% for high-versus non-high-risk patients. In addition, the only patient who progressed to accelerated phase or blast crisis had a high Sokal risk score at baseline. No data has been presented regarding differences in molecular response according to risk group. Whether meaningful differences in terms of PFS or OS according to Sokal risk emerge over time remains to be seen. The most common grade 3 or 4 nonhaematologic toxicities were skin rash (5%) musculoskeletal pains (4%), and pruritus (4%), increased serum bilirubin (16%), increased ALT (8%), increased AST (3%), increased g-GT (7%), increased lipase (8%), amylase (4%), hypophosphatemia (3%) and hyperglycaemia (3%). The most common toxicities of any grade were skin rash, musculoskeletal pains, increased bilirubin and abnormal liver transaminases, all of which were seen in at least 40% of patients. The incidence of grade 3 or 4 myelosuppression was somewhat lower in the GIMEMA study compared with the MDACC study; 4%, 3% and 0% of patients developed grade 3 or 4 neutropenia, thrombocytopenia or anaemia, respectively. Overall dose intensity was well maintained in the GIMEMA study with 74% of patients receiving a mean daily dose ranging between 600 and 800 mg. At least one interruption in treatment was reported in 52% of patients with a median duration of interruption of 19 days and only 3% of patients discontinued therapy due to toxicity. After 12 months 71% of patients were still taking at least 800mg daily. Preliminary results of the ICORG study, which is evaluating nilotinib 300 mg twice daily, suggest that equivalent results to 400 mg can be obtained with even better tolerability [O'Dwyer et al. 2010] .
Second-generation TKIs as initial treatment (phase III)
Recently data has been published from two large front-line phase III randomized trials comparing the two second-generation BCR-ABL TKIs nilotinib and dasatinib with imatinib [Kantarjian et al. 2010; Saglio et al. 2010 ]. In the nilotinib study, 846 patients with newly diagnosed ECP CML were randomized in a 1:1:1 ratio to receive nilotinib (at a dose of either 300 or 400 mg twice daily) or imatinib (at a dose of 400 mg once daily) [Saglio et al. 2010 ]. The primary end point was the rate of MMR at 12 months. At the time of analysis all patients had been followed up for a minimum of 12 months with a median duration of treatment of 14 months. At 12 months, the rates of MMR for nilotinib (44% for the 300mg dose and 43% for the 400-mg dose) were nearly twice that for imatinib (22%) (p < 0.001 for both comparisons). The rates of MMR up to the data cutoff were 57% for patients receiving 300 mg of nilotinib, 54% for those receiving 400 mg of nilotinib, and 30% for those receiving imatinib. The superiority of nilotinib was seen even in patients with high Sokal risk, with rates of MMR at 12 months 41% for patients receiving 300 mg of nilotinib, 32% for those receiving 400 mg of nilotinib, and 17% for those receiving imatinib. The rates of CCyR by 12 months, the main secondary endpoint, were significantly higher for nilotinib (80% for the 300-mg dose and 78% for the 400-mg dose) than for imatinib (65%) (p < 0.001 for both comparisons). Though improved response is important, the most important finding in this trial was the impact of nilotinib on disease progression. At the time of analysis, progression to the accelerated phase or blast crisis had occurred in 11 patients (4%) receiving imatinib, 2 patients (<1%) receiving 300 mg of nilotinib and 1 patient (<1%) receiving 400 mg of nilotinib. No patient achieving MMR subsequently progressed to accelerated phase or blast crisis. In contrast three patients receiving imatinib who achieved CCyR progressed. Both doses of nilotinib significantly increased the time to progression compared with imatinib (p ¼ 0.01 for the 300-mg group and p ¼ 0.004 for the 400-mg group). Overall, the incidence of grade 3 or 4 nonhaematologic adverse events was very low. Nausea, diarrhoea, vomiting, muscle spasm and oedema of any grade were more common with imatinib treatment, while rash, headache, pruritus and alopecia were seen more commonly with nilotinib treatment. Grade 3 or 4 neutropenia were more frequent with imatinib, while thrombocytopenia was more frequently seen with in nilotinib treatment. Grade 3 or 4 laboratory abnormalities were uncommon with all treatments, while increases of any grade in levels of liver transaminases and bilirubin were more common with nilotinib than imatinib group, although rates of discontinuation were low in all groups. No significant QT prolongation was noted in any of the treatment groups. Discontinuations because of adverse events occurred in 5% of patients receiving 300 mg of nilotinib, 9% of those receiving 400 mg of nilotinib and 7% of those receiving imatinib. While this study was not designed to see which dose of nilotinib is superior, the lower rate of discontinuation without any apparent loss in efficacy, suggests that 300 mg twice daily may be the optimal dose of nilotinib for future study in front-line CML.
In the dasatinib study 519 patients with newly diagnosed ECP CML were randomly assigned to receive dasatinib at a dose of 100 mg once daily or imatinib at a dose of 400 mg once daily [Kantarjian et al. 2010] . The primary end point was CCyR at 12 months, confirmed on two consecutive assessments at least 28 days apart. After a minimum follow up of 12 months and a median duration of treatment of 14 months, the rate of confirmed CCyR was higher with dasatinib than with imatinib (77% versus 66%, p ¼ 0.007), as was the rate of complete CCyR observed on at least one assessment (83% versus 72%, p ¼ 0.001). The rate of MMR was higher with dasatinib than with imatinib (46% versus 28%, p < 0.0001). At the time of analysis, fewer patients treated with dasatinib (1.9%) had progressed to accelerated phase or blast crisis compared with imatinib (3.5%) although with only 12 months follow up, the estimated rates of PFS were similar for patients on both treatments (96% and 97%, respectively). Importantly, no patient achieving MMR subsequently progressed to accelerated phase or blast crisis. Given the significantly higher MMR rate with dasatinib it is likely that significant differences with respect to PFS will appear over time. Grade 3 or 4 nonhaematologic toxicity was rare with most toxicity of grade 1 or 2 severity. Nausea, vomiting, muscle inflammation, rash and fluid retention occurred less frequently among patients receiving dasatinib than among those receiving imatinib. Pleural effusions were seen only following treatment with dasatinib in 26 patients (10%) and were of grade 1 (2%) or grade 2 (8%) severity only. Grade 3 or 4 neutropenia occurred with similar frequency among the patients receiving dasatinib and those receiving imatinib (21% and 20%, respectively); the rate of thrombocytopenia was 19% among patients receiving dasatinib, as compared with 10% among those receiving imatinib. One patient in each group (0.4%) had a QTc interval of greater than 500 ms. The overall rates of discontinuation of therapy due to drug toxicity were 5% among patients receiving dasatinib and 4% among those receiving imatinib. Of some concern is an increased death rate on the dasatinib arm: four patients (1.6%) on the dasatinib arm died compared with one patient (0.4%) on the imatinib arm. While one death was attributed to drug-related toxicity in each arm the recent publication does not elaborate on the cause of death of the three other dasatinib-treated patients.
Clearly, the follow up with both of these frontline phase 3 trials is short and longer follow up will be required to determine the full magnitude of difference between the new TKIs and standard-dose imatinib, to confirm that improvements in response are sustained over time and that these are associated with meaningful differences in PFS and OS. On 17 June 2010, the US Food and Drug Administration granted accelerated approval to nilotinib for the treatment of adult patients with newly diagnosed CML in the chronic phase [US Food and Drug Administration, 2010] . The recommended nilotinib dose for this indication is 300 mg orally twice daily based on a more favourable safety profile compared with 400 mg twice daily.
What can we learn from these studies? Dose intensity early in the treatment of CML does indeed appear to improve outcome, with the best results achieved thus far with the second-generation TKIs, given their greater potency and excellent tolerability. These new inhibitors have a rapid onset of action with earlier achievement of treatment goals than is usually the case with imatinib 400 mg daily, with a higher proportion of patients achieving MMR within 1 year of treatment. More importantly more potent kinase inhibition does appear to reduce the disease progression. Of over 1000 patients reported in studies of second-generation TKIs as initial therapy thus far, only 12 patients treated with second-generation TKIs are recorded as having progressed to accelerated phase or blast crisis. No data regarding the association of new mutations with resistance has yet been presented from the phase III trials but several new mutations, including E255K, F359C and T315I (2 cases), were identified in the four nilotinib-treated patients who progressed in the MDACC and GIMEMA phase II studies. Some of these patients progressed to blast crisis despite achievement of CCyR as early as 3 months, but no patient who achieved MMR subsequently progressed. While longer follow up is required, it is conceivable that beyond 1 year of therapy, the incidence of new mutations in stably responding patients will be very low, in particular as more patients achieve MMR.
Given the rapidity of response with second-generation TKIs the current criteria used for assessing adequacy of response on imatinib therapy are unsuitable for monitoring response to secondgeneration TKIs as initial therapy. A provisional definition of the response to second-generation TKIs, as second-line therapy, indicates that anything less than MCyR at 3 months, CCyR at 6 months and MMR at 12 months should be considered as suboptimal [Baccarani et al. 2009a ]. The absence of any cytogenetic response at 3 months, a minimal cytogenetic response at 6 months, less than MCyR at 12 months or the development of poorly sensitive mutations at any time are considered as treatment failure under this provisional definition. While the suboptimal component of this definition could be applied to management of newly diagnosed patients with second-generation TKIs, the definition of treatment failure is perhaps not restrictive enough for this patient population, given the availability of alternative options, such as other TKIs and even transplant. In this author's view, if a patient has failed to achieve at least MCyR by 6 months or CCyR by 12 months he or she is unlikely to do so without a change in therapy and this should be considered treatment failure.
Conclusions
The treatment of CML has evolved rapidly over the past decade with the first of the second-generation TKIs becoming a new standard in CML therapy. Potent initial therapy with second-generation TKIs, which is well tolerated, results in more rapid achievement of MMR and lower rates of disease progression, when compared with imatinib. The achievement of high rates of MMR seems important in preventing disease progression and it is hoped these benefits will ultimately translate into even better long-term survival. Clearly the emergence of resistant mutations, albeit at a low level, is a problem even for second-generation TKIs and how much of a problem this will eventually be remains to be seen. The development of newer TKIs, less prone to resistant mutations, such as T315I, could potentially lead to even better outcomes in the future. However, disease eradication remains an important goal. The identification and targeting of signalling pathways critical for the survival of BCR-ABL positive leukaemia cells, such as Wnt/Ca 2þ /NFAT, may ultimately lead to this [Gregory et al. 2010 ].
